Comparison of reduced volume versus four liters sulfate-free electrolyte lavage solutions for colonoscopy colon cleansing.
OBJECTIVE
In an attempt to improve patient tolerance for colonoscopy cleansing, a reduced volume lavage regimen with 2 L sulfate-free electrolyte lavage solution (SF-ELS, NuLYTELY, Braintree Laboratories, Braintree, MA) plus 20 mg p.o. bisacodyl (Half Lytely, Braintree Laboratories) was compared with standard 4 L SF-ELS lavage for safety and efficacy.


METHODS
At two centers, 200 patients undergoing colonoscopy for routine indications were randomized to receive the reduced volume or standard 4 L method. The day before scheduled colonoscopy, study subjects were allowed a normal breakfast and clear liquids for lunch and dinner. Those randomized to receive the reduced volume method received four 5-mg bisacodyl tablets p.o. at noon. Six hours later, they received 2 L SF-ELS given as 10 oz every 10 min. Subjects randomized to receive 4 L SF-ELS also drank their solution at 6:00 PM in a similar fashion. Colonoscopists, unaware as to the randomized preparation received, rated efficacy of cleansing. Patient tolerance and various hematological and biochemical parameters were assessed.


RESULTS
Physician assessment of colon cleansing showed no differences between those patients randomized to receive reduced volume (n = 93) or 4 L (n = 93) SF-ELS cleansing (p = 0.16). There was a profound reduction in preparation side effects. The reduced volume preparation had less fullness (p < 0.01), nausea (p < 0.01), vomiting (p = 0.01), and overall discomfort (p < 0.01). There were no clinically significant changes in hematology or blood chemistry associated with either preparation.


CONCLUSIONS
Reduced volume preparation with 2 L SF-ELS and bisacodyl is safe and effective. Clinical symptoms from the reduced volume preparation are significantly reduced compared with traditional 4 L gut lavage.
DiPalma
Jack A
JA
Division of Gastroenterology, University of South Alabama College of Medicine, Mobile, Alabama 36693, USA.
Wolff
Bruce G
BG
Meagher
Alan
A
Cleveland
Mark vB
Mv
D000328:Adult; D003110:Colonic Neoplasms / Q000517:prevention & control; D003113:Colonoscopy / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004573:Electrolytes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012016:Reference Values; D012680:Sensitivity and Specificity; D012996:Solutions / Q000627:therapeutic use; D007507:Therapeutic Irrigation / Q000379:methods*
D004573:Electrolytes; D012996:Solutions; D011092:Polyethylene Glycols; C000595212:polyethylene glycol 3350